课题基金 / 基金详情

Development of GPR30-Selective Ligands

Development of GPR30-Selective Ligands
GPR30选择性配体的开发
批准号:
7837750
负责人:
JEFFREY B ARTERBURN
金额:
$31.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-05 至 2013-05-31
关键词:
AdhesionsAffectAgonistAmerican Cancer SocietyAmino AcidsAnimal Care and Use CommitteesAnimalsAntiviral AgentsApoptosisAreaArizonaAromatic CompoundsAwardBackBasic ScienceBindingBiochemistryBioinformaticsBiologicalBiological AssayBiological ModelsBiological ProcessBiologyBiomedical ResearchBiotechnologyBlood VesselsBreastBreast Cancer TreatmentBreast CarcinomaCancer BiologyCancer CenterCancer PatientCancer Research ProjectCarbohydratesCell AdhesionCell NucleusCellular AssayCervix UteriCessation of lifeChemicalsChemistryCollectionComplementComplexCytometryDataDevelopmentDiseaseDoctor of PhilosophyDrug Delivery SystemsDrug IndustryEndometrial CarcinomaEndometriumEpidermal Growth Factor ReceptorEstradiolEstrogen AntagonistsEstrogen Nuclear ReceptorEstrogen Receptor 2Estrogen ReceptorsEstrogensFemaleFlow CytometryFoundationsFundingG Protein-Coupled Receptor GenesGTP-Binding ProteinsGoalsGrantGrowthGrowth and Development functionHomeostasisHormonesHuman bodyImmune systemIncidenceInstitutesLabelLaboratoriesLeadLeadershipLegal patentLeukocytesLibrariesLigand BindingLigandsMalignant NeoplasmsMammary Gland ParenchymaMammary NeoplasmsMediatingMediator of activation proteinMembraneMolecularMolecular BankMolecular and Cellular BiologyNational Institute of Allergy and Infectious DiseaseNational Institute of Environmental Health SciencesNational Institute of General Medical SciencesNatureNew MexicoNucleosidesOvaryPathologyPharmaceutical ChemistryPhosphatidylinositolsPhosphorylationPhysiologicalPhysiologyPlayPostdoctoral FellowPublicationsPublishingQuantitative Structure-Activity RelationshipRadioisotopesRecruitment ActivityRegulationReproductionReproductive BiologyResearchResearch ProposalsResource SharingResourcesRoleScienceScreening ResultScreening procedureSelective Estrogen Receptor ModulatorsSignal PathwaySignal TransductionSocietiesStructureStructure-Activity RelationshipStudy SectionSwedenSynthesis ChemistryTNFRSF5 geneTamoxifenTechnologyTherapeuticTherapeutic AgentsTherapeutic InterventionTimeTissuesTranscriptional ActivationUnited StatesUnited States National Institutes of HealthUniversitiesWashingtonWomanWorkanticancer researchbasecell motilitychemical propertycheminformaticscomputer studiesdesigndrug discoveryexperiencefeedingfemale reproductive systemimprovedin vivomalignant breast neoplasmmembermodel developmentmolecular assembly/self assemblymouse modelneoplasticnew technologynoveloverexpressionprofessorprogramspublic health relevancereceptorrelease of sequestered calcium ion into cytoplasmreproductiveresearch and developmentresponseskeletalsmall moleculetooltraffickingtreatment centervirtual

项目摘要

项目成果

JEFFREY B ARTERBURN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Estrogen is a critical hormone in the human body that regulates the growth, development and homeostasis of many tissues. Physiological responses to estrogen include the regulation of mammalian reproduction and breast function, central nervous and immune systems, skeletal physiology and vascular function. We have recently described novel functions of the seven transmembrane G protein-coupled estrogen receptor, GPR30. This receptor is activated by both agonists and antagonists of the classical estrogen receptors, ER1 and ER2. Until recently there were no known specific ligands for GPR30, making traditional pharmacological approaches to the study of this receptor difficult. Our recent studies however have combined both virtual and biomolecular screening to discover the first GPR30-selective agonist, G-1. The specific aims of this application are: 1. Perform a combination of virtual and biomolecular screening to identify additional GPR30-specific ligands based on compounds presently known to bind and activate GPR30. Structure-activity analyses will be carried out to determine the critical molecular determinants for GPR30 binding selectivity and activity as compared to classical estrogen receptors. 2. Based on the biomolecular screening results and structure-activity analyses of Aim 1, rationally design and synthesize small libraries (up to 20 compounds per cycle) of novel G-1-based ligands. The goal of this aim is to separate agonism from antagonism within ligands, and to further evaluate the SAR of novel GPR30 ligands through targeted synthetic chemistry. 3. Characterize the biological functions of the compounds identified and synthesized in Aims 1 and 2. A collection of functional bioassays will be employed to characterize the biological effects of the compounds displaying activity. These assays will include intracellular signaling assays such as calcium mobilization, ERK and EGFR phosphorylation and PI3K activation; more complex cellular assays such as transcriptional activation, cell migration and proliferation; and in vivo studies using mouse models. Understanding the pharmacological profile and structure-activity relationships for ligand binding to GPR30 will be critical to the discovery of novel drugs that target this receptor for the purposes of revealing the underlying physiology of the receptor and developing therapeutic approaches for the improved treatment of estrogen-dependent cancers. PUBLIC HEALTH RELEVANCE: Estrogen plays an important role in normal and disease biology. We have characterized a novel membrane estrogen receptor that likely plays a role in estrogen biology. The goal of this work is to develop novel compounds that can specifically target this new receptor to either activate or inhibit its activity without affecting other estrogen receptors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands
海外基金